The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Glyburide inhibits the Cryopyrin/Nalp3 inflammasome
Open accessAbstract
Inflammasomes activate caspase-1 for processing and secretion of the cytokines interleukin-1beta (IL-1beta) and IL-18. Cryopyrin/NALP3/NLRP3 is an essential component of inflammasomes triggered by microbial ligands, danger-associated molecular patterns (DAMPs), and crystals. Inappropriate Cryopyrin activity has been incriminated in the pathogenesis of gouty arthritis, Alzheimer's, and silicosis. Therefore, inhibitors of the Nalp3 inflammasome offer considerable therapeutic promise. In this study, we show that the type 2 diabetes drug glyburide prevented activation of the Cryopyrin inflammasome. Glyburide's cyclohexylurea group, which binds to adenosine triphosphatase (ATP)-sensitive K(+) (K(ATP)) channels for insulin secretion, is dispensable for inflammasome inhibition. Macrophages lacking K(ATP) subunits or ATP-binding cassette transporters also activate the Cryopyrin inflammasome normally. Glyburide analogues inhibit ATP- but not hypothermia-induced IL-1beta secretion from human monocytes expressing familial cold-associated autoinflammatory syndrome-associated Cryopyrin mutations, thus suggesting that inhibition occurs upstream of Cryopyrin. Concurrent with the role of Cryopyrin in endotoxemia, glyburide significantly delays lipopolysaccharide-induced lethality in mice. Therefore, glyburide is the first identified compound to prevent Cryopyrin activation and microbial ligand-, DAMP-, and crystal-induced IL-1beta secretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glyburide is a commonly used sulfonylurea drug for the treatment of type 2 diabetes and was recently shown to inhibit the NLRP-3 inflammasome through a mechanism that appears to be different from that involved in its ability to promote insulin secretion from pancreatic β-cells (38).”
From Sustained Inflammasome Activity in Macrophages Impairs Wound Healing in Type 2 Diabetic Humans and Mice (2014) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Cryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080
Self-citationHornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf
Mariathasan, S., Newton, K., Monack, D. M., Vucic, D., French, D. M., Lee, W. P., Roose-Girma, M., Erickson, S. L., & Dixit, V. M. (2004) · Nature · doi:10.1038/nature02664 · Cited by 1,864
Self-citationHoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,679
Self-citationPannexin‐1 mediates large pore formation and interleukin‐1β release by the ATP‐gated P2X7 receptor
Pelegrı́n, P., & Surprenant, A. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601378 · Cited by 1,490
Cloning of the β Cell High-Affinity Sulfonylurea Receptor: a Regulator of Insulin Secretion
Aguilar-Bryan, L., Nichols, C. G., Wechsler, S. W., Clement, J. P., Boyd, A. E., González, G., Herrera-Sosa, H., Nguy, K., Bryan, J., & Nelson, D. A. (1995) · Science · doi:10.1126/science.7716547 · Cited by 1,315
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T., Özören, N., Body–Malapel, M., Amer, A. O., Park, J., Franchi, L., Whitfield, J. R., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,149
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–832 of 832
Clinical efficacy of guided tissue regeneration combined with orthodontic treatment on periodontitis
Wang, F., Yang, F., Yao, C., & Du, Y. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1803582
Jia, D., Hou, Y., Wu, Y., Zhang, Y., Zhao, Y., & Gong, P. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00563b
Ma, M., Zhang, M., Sun, H., Xie, X., Guo, X., Li, H., & Jin, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924802
Tsai, C. C., & Lo, Y. (2026) · Dermatologica Sinica · doi:10.4103/ds.ds-d-25-00251
Zhang, X., Li, Y., Li, H., Lin, C., & Tao, H. (2026) · International Endodontic Journal · doi:10.1111/iej.70224
Yin, X., Zhu, Q., Zhao, L., Ma, W., Wang, L., Li, H., Wang, C., Wang, Y., Xu, L., Zhang, H., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117627
Pyroptosis in myocardial ischemia-reperfusion injury: mechanistic pathways and therapeutic prospects
Ding, S., Zhang, X., Sheng, Z., Wang, Y., & 方, 五. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1938791
BindingDB Entry 50017788: Synthesis and Pharmacological Evaluation of New
BindingDB (2023) · UC San Diego · doi:10.7270/q2mp57d8
BindingDB Entry 50020719: Recent advances in gout drugs.
BindingDB (2024) · UC San Diego · doi:10.7270/q2m049xj
BindingDB Entry 50047235: Inhibiting the Inflammasome: A Chemical Perspective.
BindingDB (2017) · UC San Diego · doi:10.7270/q2416zzm
BindingDB (2024) · UC San Diego · doi:10.7270/q2dv1qcz
BindingDB Entry 50020563: Discovery of Novel 2,3-Dihydro-1
BindingDB (2024) · UC San Diego · doi:10.7270/q2cz3cmf
Chojnacki, J. E. (2014) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/62wy-9639
Investigating the contribution of the inflammasome to persistent pain states
Ellis, A. (2013) · UPT. Syiah Kuala University Library (Syiah Kuala University)
Metadata
- Authors
- Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., Lee, W. P., Hoffman, H. M., & Dixit, V. M.
- Affiliations
- Genentech (US)
- University of California San Diego (US)
- Corresponding author
- Dixit, Vishva M.
- Venue
- Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2009-10-05
- Volume
- 187
- Issue
- 1
- Pages
- 61-70
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC2762099
- OpenAlex
- W2134007048
- Cited by
- 820
- References
- 35
- Citations by year
- 2026: 25 · 2025: 44 · 2024: 63 · 2023: 50 · 2022: 67 · 2021: 52 · 2020: 66 · 2019: 64 · 2018: 62 · 2017: 47 · 2016: 42 · 2015: 68 · 2014: 47 · 2013: 44 · 2012: 31
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Cell Biology (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI052430)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Keywords
- glibenclamide, NLRP3 inflammasome, NLRP3, caspase-1, IL-1β, IL-18, ATP-sensitive potassium channels, ABC transporters, monocytes, lipopolysaccharide, endotoxemia, gout, type 2 diabetes drugs, inflammasome inhibitors
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Adenosine Triphosphatases, Adenosine Triphosphate, Animals, Carrier Proteins, Cells, Cultured, Enzyme Activation, Glyburide, Humans, Hypoglycemic Agents, Inflammation, Lipopolysaccharides, Macrophages, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Monocytes, Mutation, Random Allocation, Salmonella typhimurium, Mice, Knockout, Caspase 1, Interleukin-18, Mice, Interleukin-1beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
